In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d.
Ann Intern Med
; 176(2): JC17, 2023 02.
Article
in English
| MEDLINE | ID: covidwho-2235316
ABSTRACT
SOURCE CITATION Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and aspirin in community patients with COVID-19 (ACT) an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022;101160-8. 36228639.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Aspirin
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Ann Intern Med
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS